Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update

Isaac Yen-Hao Chu, Stephane Wen-Wei Ku, Chia Wen Li, Han Siong Toh, Chia Jui Yang, Kuan Sheng Wu, Huei Jiuan Wu, Shu Sheng Chen, Jiann Horng Kuo, Hsi Hsun Lin, Nai Ying Ko

Research output: Contribution to journalReview article

Abstract

Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen.

Original languageEnglish
JournalJournal of Microbiology, Immunology and Infection
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Taiwan
HIV
Guidelines
Transgender Persons
Tenofovir
Heterosexuality
Pre-Exposure Prophylaxis
Databases
Manuscripts
Virus Diseases
Centers for Disease Control and Prevention (U.S.)
PubMed
Population
Publications
Consensus
Acquired Immunodeficiency Syndrome
Referral and Consultation
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Yen-Hao Chu, Isaac ; Wen-Wei Ku, Stephane ; Li, Chia Wen ; Toh, Han Siong ; Yang, Chia Jui ; Wu, Kuan Sheng ; Wu, Huei Jiuan ; Chen, Shu Sheng ; Kuo, Jiann Horng ; Lin, Hsi Hsun ; Ko, Nai Ying. / Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update. In: Journal of Microbiology, Immunology and Infection. 2019.
@article{270cfc9ea7764ebfbe0ec28c1326cdbd,
title = "Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update",
abstract = "Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen.",
author = "{Yen-Hao Chu}, Isaac and {Wen-Wei Ku}, Stephane and Li, {Chia Wen} and Toh, {Han Siong} and Yang, {Chia Jui} and Wu, {Kuan Sheng} and Wu, {Huei Jiuan} and Chen, {Shu Sheng} and Kuo, {Jiann Horng} and Lin, {Hsi Hsun} and Ko, {Nai Ying}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jmii.2019.09.003",
language = "English",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "1684-1182",
publisher = "Elsevier Taiwan LLC",

}

Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update. / Yen-Hao Chu, Isaac; Wen-Wei Ku, Stephane; Li, Chia Wen; Toh, Han Siong; Yang, Chia Jui; Wu, Kuan Sheng; Wu, Huei Jiuan; Chen, Shu Sheng; Kuo, Jiann Horng; Lin, Hsi Hsun; Ko, Nai Ying.

In: Journal of Microbiology, Immunology and Infection, 01.01.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update

AU - Yen-Hao Chu, Isaac

AU - Wen-Wei Ku, Stephane

AU - Li, Chia Wen

AU - Toh, Han Siong

AU - Yang, Chia Jui

AU - Wu, Kuan Sheng

AU - Wu, Huei Jiuan

AU - Chen, Shu Sheng

AU - Kuo, Jiann Horng

AU - Lin, Hsi Hsun

AU - Ko, Nai Ying

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen.

AB - Pre-exposure prophylaxis (PrEP) for prevention of human immunodeficiency virus infection is proved to be effective and has been implemented worldwide. This article introduces the guideline development and revised recommendations and guidance on PrEP provision in the updated Taiwan PrEP guideline. The Taiwan PrEP guideline writing group searched randomized controlled trials and guidelines published before October 2017 through Medline/PubMed, Cochrane Database, Embase and ClinicalTrials.gov database. Keywords included pre(-)exposure prophylaxis, PrEP, Truvada, tenofovir, HIV, and AIDS. Each selected article was assessed by two authors using the Grading of Recommendations Assessment, Development and Evaluation. External reviewers were invited to independently evaluate the revised manuscript per the Appraisal of Guidelines for Research and Evaluation II. Before publication, a public consultation was held to reach consensus on the updated guideline among providers, civil society, and Taiwan Centers for Disease Control. Four systematic reviews and 28 original articles were reviewed by Taiwan PrEP writing group. The second version of the Taiwan PrEP guideline was released in March 2018. We recommended daily PrEP use for the following populations: strong recommendation and high quality of evidence for men who have sex with men (MSM) and transgender women (TGW), as well as heterosexual serodiscordant couples; weak recommendation and high quality of evidence for people who inject drugs, while weak recommendation and moderate quality of evidence for at-risk heterosexual men and women. There is high-quality evidence for event-driven PrEP in MSM and likely TGW, and we additionally recognized these key populations could benefit from such dosing regimen.

UR - http://www.scopus.com/inward/record.url?scp=85073574751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073574751&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2019.09.003

DO - 10.1016/j.jmii.2019.09.003

M3 - Review article

AN - SCOPUS:85073574751

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 1684-1182

ER -